Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's ChemGenex Reaches Agreement With U.S. FDA To Re-file Omapro NDA For Third-Line CML Treatment

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - The chief executive officer of Melbourne-headquartered ChemGenex told investors and analysts July 14 that the company has reached agreement with U.S. FDA for a regulatory pathway forward of its Omapro (omacetaxine) new drug application for third-line treatment of chronic myeloid leukemia for patients who have failed multiple tyrosine kinase inhibitors
Advertisement

Related Content

Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex
Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex
FDA will let ChemGenex file Omapro in third-line CML with no mutation test required
FDA will let ChemGenex file Omapro in third-line CML with no mutation test required
Australian ChemGenex Readies Omapro For Second NDA Despite U.S. FDA Setbacks
U.S. FDA Says Australian ChemGenex Needs Companion Diagnostic For Omapro
U.S. FDA Says Australian ChemGenex Needs Companion Diagnostic For Omapro
Australian ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
Advertisement
UsernamePublicRestriction

Register

SC075334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel